Top

Published in:

Open Access 01-12-2021 | Heart Failure | Original investigation

Incidence of atrial fibrillation, ischaemic heart disease and heart failure in patients with diabetes

Authors: Amy Groenewegen, Victor W. Zwartkruis, Betül Cekic, Rudolf. A. de Boer, Michiel Rienstra, Arno W. Hoes, Frans H. Rutten, Monika Hollander

Published in: Cardiovascular Diabetology | Issue 1/2021

Abstract

Background

Diabetes has strongly been linked to atrial fibrillation, ischaemic heart disease and heart failure. The epidemiology of these cardiovascular diseases is changing, however, due to changes in prevalence of obesity-related conditions and preventive measures. Recent population studies on incidence of atrial fibrillation, ischaemic heart disease and heart failure in patients with diabetes are needed.

Methods

A dynamic longitudinal cohort study was performed using primary care databases of the Julius General Practitioners’ Network. Diabetes status was determined at baseline (1 January 2014 or upon entering the cohort) and participants were followed-up for atrial fibrillation, ischaemic heart disease and heart failure until 1 February 2019. Age and sex-specific incidence and incidence rate ratios were calculated.

Results

Mean follow-up was 4.2 years, 12,168 patients were included in the diabetes group, and 130,143 individuals in the background group. Incidence rate ratios, adjusted for age and sex, were 1.17 (95% confidence interval 1.06–1.30) for atrial fibrillation, 1.66 (1.55–1.83) for ischaemic heart disease, and 2.36 (2.10–2.64) for heart failure. Overall, incidence rate ratios were highest in the younger age categories, converging thereafter.

Conclusion

There is a clear association between diabetes and incidence of the major chronic progressive heart diseases, notably with heart failure with a more than twice increased risk.

Available only for authorised users

Shah AD, Langenberg C, Rapsomaniki E, et al. Type 2 diabetes and incidence of cardiovascular diseases: A cohort study in 1·9 million people. Lancet Diabetes Endocrinol. 2015;3(2):105–13. https://doi.org/10.1016/S2213-8587(14)70219-0.CrossRefPubMedPubMedCentral

Naghavi M, Abajobir AA, Abbafati C, et al. Global, regional, and national age-sex specifc mortality for 264 causes of death, 1980–2016: A systematic analysis for the Global Burden of Disease Study 2016. The Lancet. 2017;390(10100):1151–210. https://doi.org/10.1016/S0140-6736(17)32152-9.CrossRef

Mensah GA, Wei GS, Sorlie PD, et al. (2017) Decline in Cardiovascular Mortality: Possible Causes and Implications. In. Vol 120. Lippincott Williams and Wilkins, pp 366–380

Moradi M, Daneshi F, Behzadmehr R, Rafiemanesh H, Bouya S, Raeisi M (2020) Quality of life of chronic heart failure patients: a systematic review and meta-analysis. In. Vol 25. Springer, pp 993–1006

Schweikert B, Hunger M, Meisinger C, König HH, Gapp O, Holle R. Quality of life several years after myocardial infarction: Comparing the MONICA/KORA registry to the general population. Eur Heart J. 2009. https://doi.org/10.1093/eurheartj/ehn509.CrossRefPubMed

Dégano IR, Salomaa V, Veronesi G, et al. Twenty-five-year trends in myocardial infarction attack and mortality rates, and case-fatality, in six European populations. Heart. 2015;101(17):1413–21. https://doi.org/10.1136/heartjnl-2014-307310.CrossRefPubMed

Smolina K, Wright FL, Rayner M, Goldacre MJ. Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study. BMJ (Clinical research ed). 2012;344:d8059–d8059. https://doi.org/10.1136/bmj.d8059.CrossRef

Unal B, Critchley JA, Capewell S. Explaining the Decline in Coronary Heart Disease Mortality in England and Wales between 1981 and 2000. Circulation. 2004;109(9):1101–7. https://doi.org/10.1161/01.CIR.0000118498.35499.B2.CrossRefPubMed

Gerber Y, Weston SA, Redfield MM, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015;175(6):996–1004. https://doi.org/10.1001/jamainternmed.2015.0924.CrossRefPubMedPubMedCentral

10.

Christiansen MN, Køber L, Weeke P, et al. Age-Specific Trends in Incidence, Mortality, and Comorbidities of Heart Failure in Denmark, 1995 to 2012. Circulation. 2017;135(13):1214–23. https://doi.org/10.1161/CIRCULATIONAHA.116.025941.CrossRefPubMed

11.

Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119–25. https://doi.org/10.1161/CIRCULATIONAHA.105.595140.CrossRefPubMed

12.

Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013;34(35):2746–51. https://doi.org/10.1093/eurheartj/eht280.CrossRefPubMedPubMedCentral

13.

Huxley RR, Lopez FL, Folsom AR, et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: The atherosclerosis risk in communities (ARIC) study. Circulation. 2011;123(14):1501–8. https://doi.org/10.1161/CIRCULATIONAHA.110.009035.CrossRefPubMedPubMedCentral

14.

Palmieri L, Veronesi G, Corrao G, et al. Cardiovascular diseases monitoring: Lessons from population-based registries to address future opportunities and challenges in Europe. Archives of Public Health. 2018;76(1):31–31. https://doi.org/10.1186/s13690-018-0283-3.CrossRefPubMedPubMedCentral

15.

Pfeffer MA, Shah AM, Borlaug BA. Heart Failure With Preserved Ejection Fraction In Perspective. Circ Res. 2019;124(11):1598–617. https://doi.org/10.1161/CIRCRESAHA.119.313572.CrossRefPubMedPubMedCentral

16.

Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: The cardiovascular health study. J Am Coll Cardiol. 2000;35(6):1628–37. https://doi.org/10.1016/S0735-1097(00)00582-9.CrossRefPubMed

17.

Pallisgaard JL, Schjerning AM, Lindhardt TB, et al. Risk of atrial fibrillation in diabetes mellitus: A nationwide cohort study. Eur J Prev Cardiol. 2016;23(6):621–7. https://doi.org/10.1177/2047487315599892.CrossRefPubMed

18.

Sarwar N, Gao P, Kondapally Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. The Lancet. 2010;375(9733):2215–22. https://doi.org/10.1016/S0140-6736(10)60484-9.CrossRef

19.

Acharya T, Deedwania PC. (2018) The Role of Newer Anti-Diabetic Drugs in Cardiovascular Disease - American College of Cardiology. Available from https://www.acc.org/latest-in-cardiology/articles/2018/05/22/16/59/the-role-of-newer-anti-diabetic-drugs-in-cv-disease. Accessed 11 Nov 2020.

20.

Smeets HM, Kortekaas MF, Rutten FH, et al. Routine primary care data for scientific research, quality of care programs and educational purposes: the Julius General Practitioners’ Network (JGPN). BMC Health Serv Res. 2018;18(1):735–735. https://doi.org/10.1186/s12913-018-3528-5.CrossRefPubMedPubMedCentral

21.

Lee CD, Folsom AR, Pankow JS, Brancati FL. Cardiovascular Events in Diabetic and Nondiabetic Adults With or Without History of Myocardial Infarction. Circulation. 2004;109:855–60. https://doi.org/10.1161/01.CIR.0000116389.61864.DE.CrossRefPubMed

22.

Ho JE, Enserro D, Brouwers FP, et al. (2016) Predicting Heart Failure with Preserved and Reduced Ejection Fraction: The International Collaboration on Heart Failure Inftypes. Circulation: Heart Failure 9(6): 1–9. https://doi.org/10.1161/CIRCHEARTFAILURE.115.003116

23.

Amato L, Paolisso G, Cacciatore F, et al. (1997) Congestive Heart Failure Predicts the Development of Non-Insulin-Dependent Diabetes Mellitus in the Elderly. Diabetes & Metabolism (Paris)

24.

Savji N, Meijers WC, Bartz TM, et al. (2018) The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF. JACC: Heart Failure 6(8): 701–709. https://doi.org/10.1016/j.jchf.2018.05.018

25.

De Boer RA, Nayor M, DeFilippi CR, et al. Association of cardiovascular biomarkers with incident heart failure with preserved and reduced ejection fraction. JAMA Cardiology. 2018;3(3):215–24. https://doi.org/10.1001/jamacardio.2017.4987.CrossRefPubMedPubMedCentral

26.

Kannel WB, McGee DL (1979) Diabetes and cardiovascular disease. The Framingham study. JAMA. https://doi.org/10.1001/jama.1979.03290450033020

27.

Ohkuma T, Komorita Y, Peters SAE, Woodward M. Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals. Diabetologia. 2019;62(9):1550–60. https://doi.org/10.1007/s00125-019-4926-x.CrossRefPubMedPubMedCentral

28.

Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000;321(7258):405–12.CrossRef

29.

Boonman-De Winter LJM, Rutten FH, Cramer MJ, et al. Efficiently screening heart failure in patients with type 2 diabetes. Eur J Heart Fail. 2015;17(2):187–95. https://doi.org/10.1002/ejhf.216.CrossRefPubMed

30.

Muhlestein JB, Lappé DL, Lima JAC, et al. Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: The FACTOR-64 randomized clinical trial. JAMA - Journal of the American Medical Association. 2014;312(21):2234–43. https://doi.org/10.1001/jama.2014.15825.CrossRefPubMed

31.

Wackers FJT, Young LH, Inzucchi SE, et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: The DIAD study. Diabetes Care. 2004;27(8):1954–61. https://doi.org/10.2337/diacare.27.8.1954.CrossRefPubMed

32.

Malhotra S, Sharma R, Kliner DE, Follansbee WP, Soman P. Relationship between silent myocardial ischemia and coronary artery disease risk factors. J Nucl Cardiol. 2013;20(5):731–8. https://doi.org/10.1007/s12350-013-9708-0.CrossRefPubMed

33.

Potpara TS, Polovina MM, Marinkovic JM, Lip GYH. A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: The Belgrade Atrial Fibrillation Study. Int J Cardiol. 2013;168(5):4744–9. https://doi.org/10.1016/j.ijcard.2013.07.234.CrossRefPubMed

34.

De Ferranti SD, De Boer IH, Fonseca V, et al. (2014) Type 1 diabetes mellitus and cardiovascular disease: A scientific statement from the American Heart Association and American Diabetes Association. In. Vol 37. American Diabetes Association Inc., pp 2843–2863

35.

Xu G, Liu B, Sun Y, et al. Prevalence of diagnosed type 1 and type 2 diabetes among US adults in 2016 and 2017: Population based study. BMJ (Online). 2018. https://doi.org/10.1136/bmj.k1497.CrossRef

Title: Incidence of atrial fibrillation, ischaemic heart disease and heart failure in patients with diabetes
Authors: Amy Groenewegen
Victor W. Zwartkruis
Betül Cekic
Rudolf. A. de Boer
Michiel Rienstra
Arno W. Hoes
Frans H. Rutten
Monika Hollander
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Heart Failure
Atrial Fibrillation
Published in: Cardiovascular Diabetology / Issue 1/2021
Electronic ISSN: 1475-2840
DOI: https://doi.org/10.1186/s12933-021-01313-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Role of obesity and hypertension in the incidence of atrial fibrillation, ischaemic heart disease and heart failure in patients with diabetes

Association of diabetes mellitus with clinical outcomes in patients with different coronary artery stenosis

Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes

Cardiovascular and mortality benefits of sodium–glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia

Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data

Triglyceride-glucose index and the risk of stroke and its subtypes in the general population: an 11-year follow-up

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials